ReP USP - Resultado da busca

Artigo de periodico
The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer (2019)
Marchi, Pedro De; Melendez, Matias E; Laus, Ana C; Kuhlmann, Pamela A; Carvalho, Ana Carolina de; Arantes, Lidia Maria R. B; Evangelista, Adriane F; Andrade, Edilene S; Castro Junior, Gilberto de Castro ; Reis, Rui M
Fonte: Oral oncology. Unidade: FM
Assuntos: NEOPLASIAS DE CABEÇA E PESCOÇO, POLIMORFISMO, CARCINOMA DE CÉLULAS ESCAMOSAS, SEQUENCIAMENTO GENÉTICO, QUIMIOTERAPIA, ANTINEOPLÁSICOS, PROTEÍNAS DE TRANSPORTE, GENÓTIPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARCHI, Pedro De et al. The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. Oral oncology, v. 98, p. 48-52, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.oraloncology.2019.09.013. Acesso em: 06 nov. 2024.
APA
Marchi, P. D., Melendez, M. E., Laus, A. C., Kuhlmann, P. A., Carvalho, A. C. de, Arantes, L. M. R. B., et al. (2019). The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer. Oral oncology, 98, 48-52. doi:10.1016/j.oraloncology.2019.09.013
NLM
Marchi PD, Melendez ME, Laus AC, Kuhlmann PA, Carvalho AC de, Arantes LMRB, Evangelista AF, Andrade ES, Castro Junior G de C, Reis RM. The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer [Internet]. Oral oncology. 2019 ; 98 48-52.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.oraloncology.2019.09.013
Vancouver
Marchi PD, Melendez ME, Laus AC, Kuhlmann PA, Carvalho AC de, Arantes LMRB, Evangelista AF, Andrade ES, Castro Junior G de C, Reis RM. The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer [Internet]. Oral oncology. 2019 ; 98 48-52.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.oraloncology.2019.09.013
Artigo de periodico
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial (2019)
Herbst, R. S; Baas, P; Perez-gracia, J. L; Felip, E; Kim, D. -W; Han, J. -Y; Molina, J. R; Kim, J. -H; Arvis, C. Dubos; Castro Junior, Gilberto de
Fonte: Annals of oncology. Unidade: FM
Assuntos: IMUNOHISTOQUÍMICA, ANTINEOPLÁSICOS, NEOPLASIAS PULMONARES, CÉLULAS CULTIVADAS DE TUMOR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HERBST, R. S et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of oncology, v. 30, n. 2, p. 281-289, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdy545. Acesso em: 06 nov. 2024.
APA
Herbst, R. S., Baas, P., Perez-gracia, J. L., Felip, E., Kim, D. -W., Han, J. -Y., et al. (2019). Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of oncology, 30( 2), 281-289. doi:10.1093/annonc/mdy545
NLM
Herbst RS, Baas P, Perez-gracia JL, Felip E, Kim D-W, Han J-Y, Molina JR, Kim J-H, Arvis CD, Castro Junior G de. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [Internet]. Annals of oncology. 2019 ; 30( 2): 281-289.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1093/annonc/mdy545
Vancouver
Herbst RS, Baas P, Perez-gracia JL, Felip E, Kim D-W, Han J-Y, Molina JR, Kim J-H, Arvis CD, Castro Junior G de. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [Internet]. Annals of oncology. 2019 ; 30( 2): 281-289.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1093/annonc/mdy545
Artigo de periodico
Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC (2019)
Barlesi, Fabrice; Garon, Edward B; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; Castro Junior, Gilberto de
Fonte: Journal of thoracic oncology. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, QUIMIOTERAPIA, QUALIDADE DE VIDA, IMUNOHISTOQUÍMICA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARLESI, Fabrice et al. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, v. 14, n. 5, p. 793-801, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.01.016. Acesso em: 06 nov. 2024.
APA
Barlesi, F., Garon, E. B., Kim, D. -W., Felip, E., Han, J. -Y., Kim, J. -H., et al. (2019). Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, 14( 5), 793-801. doi:10.1016/j.jtho.2019.01.016
NLM
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016
Vancouver
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016
Artigo de periodico
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019)
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro ; Psyrri, Amanda; Baste, Neus; Neupane, Prakash; Bratland, Ase
Fonte: Lancet. Unidade: FM
Assuntos: CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS DE CABEÇA E PESCOÇO, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, v. 394, n. 10212, p. 1915-1928, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)32591-7. Acesso em: 06 nov. 2024.
APA
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394( 10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7
NLM
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Vancouver
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7

Unidades USP

ReP

Filtros

Autores

Assuntos

Agência de fomento